vs
DNOW Inc.（DNOW）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
DNOW Inc.的季度营收约是Revvity的1.2倍（$959.0M vs $772.1M），Revvity净利率更高（12.7% vs -16.8%，领先29.5%），DNOW Inc.同比增速更快（68.0% vs 5.9%），Revvity自由现金流更多（$161.8M vs $76.0M），过去两年DNOW Inc.的营收复合增速更高（30.5% vs 9.0%）
DNOW Inc.（商业名称DistributionNOW）是一家全球工业及能源产品分销商，提供供应链管理、库存优化、技术支持服务，主营油气、可再生能源、制造、建筑等领域所需的零部件、设备及耗材，业务覆盖北美、欧洲及亚太地区。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DNOW vs RVTY — 直观对比
营收规模更大
DNOW
是对方的1.2倍
$772.1M
营收增速更快
DNOW
高出62.1%
5.9%
净利率更高
RVTY
高出29.5%
-16.8%
自由现金流更多
RVTY
多$85.8M
$76.0M
两年增速更快
DNOW
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $959.0M | $772.1M |
| 净利润 | $-161.0M | $98.4M |
| 毛利率 | 5.2% | — |
| 营业利润率 | -19.6% | 14.5% |
| 净利率 | -16.8% | 12.7% |
| 营收同比 | 68.0% | 5.9% |
| 净利润同比 | -905.0% | 3.9% |
| 每股收益（稀释后） | $-1.42 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNOWRVTY
| Q4 25 | $959.0M | $772.1M | ||
| Q3 25 | $634.0M | $698.9M | ||
| Q2 25 | $628.0M | $720.3M | ||
| Q1 25 | $599.0M | $664.8M | ||
| Q4 24 | $571.0M | $729.4M | ||
| Q3 24 | $606.0M | $684.0M | ||
| Q2 24 | $633.0M | $691.7M | ||
| Q1 24 | $563.0M | $649.9M |
净利润DNOWRVTY
| Q4 25 | $-161.0M | $98.4M | ||
| Q3 25 | $25.0M | $46.7M | ||
| Q2 25 | $25.0M | $53.9M | ||
| Q1 25 | $22.0M | $42.2M | ||
| Q4 24 | $20.0M | $94.6M | ||
| Q3 24 | $13.0M | $94.4M | ||
| Q2 24 | $24.0M | $55.4M | ||
| Q1 24 | $21.0M | $26.0M |
毛利率DNOWRVTY
| Q4 25 | 5.2% | — | ||
| Q3 25 | 22.9% | 53.6% | ||
| Q2 25 | 22.9% | 54.5% | ||
| Q1 25 | 23.2% | 56.5% | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 22.3% | 56.3% | ||
| Q2 24 | 21.8% | 55.7% | ||
| Q1 24 | 22.9% | 54.6% |
营业利润率DNOWRVTY
| Q4 25 | -19.6% | 14.5% | ||
| Q3 25 | 5.2% | 11.7% | ||
| Q2 25 | 5.1% | 12.6% | ||
| Q1 25 | 5.0% | 10.9% | ||
| Q4 24 | 4.4% | 16.3% | ||
| Q3 24 | 3.8% | 14.3% | ||
| Q2 24 | 5.2% | 12.4% | ||
| Q1 24 | 5.0% | 6.8% |
净利率DNOWRVTY
| Q4 25 | -16.8% | 12.7% | ||
| Q3 25 | 3.9% | 6.7% | ||
| Q2 25 | 4.0% | 7.5% | ||
| Q1 25 | 3.7% | 6.4% | ||
| Q4 24 | 3.5% | 13.0% | ||
| Q3 24 | 2.1% | 13.8% | ||
| Q2 24 | 3.8% | 8.0% | ||
| Q1 24 | 3.7% | 4.0% |
每股收益（稀释后）DNOWRVTY
| Q4 25 | $-1.42 | $0.86 | ||
| Q3 25 | $0.23 | $0.40 | ||
| Q2 25 | $0.23 | $0.46 | ||
| Q1 25 | $0.20 | $0.35 | ||
| Q4 24 | $0.19 | $0.77 | ||
| Q3 24 | $0.12 | $0.77 | ||
| Q2 24 | $0.21 | $0.45 | ||
| Q1 24 | $0.19 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $164.0M | $919.9M |
| 总债务越低越好 | $411.0M | — |
| 股东权益账面价值 | $2.2B | $7.3B |
| 总资产 | $3.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.18× | — |
8季度趋势，按日历期对齐
现金及短期投资DNOWRVTY
| Q4 25 | $164.0M | $919.9M | ||
| Q3 25 | $266.0M | $931.4M | ||
| Q2 25 | $232.0M | $991.8M | ||
| Q1 25 | $219.0M | $1.1B | ||
| Q4 24 | $256.0M | $1.2B | ||
| Q3 24 | $261.0M | $1.2B | ||
| Q2 24 | $197.0M | $2.0B | ||
| Q1 24 | $188.0M | $1.7B |
总债务DNOWRVTY
| Q4 25 | $411.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DNOWRVTY
| Q4 25 | $2.2B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.1B | $7.8B |
总资产DNOWRVTY
| Q4 25 | $3.9B | $12.2B | ||
| Q3 25 | $1.7B | $12.1B | ||
| Q2 25 | $1.7B | $12.4B | ||
| Q1 25 | $1.7B | $12.4B | ||
| Q4 24 | $1.6B | $12.4B | ||
| Q3 24 | $1.6B | $12.8B | ||
| Q2 24 | $1.6B | $13.4B | ||
| Q1 24 | $1.6B | $13.4B |
负债/权益比DNOWRVTY
| Q4 25 | 0.18× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $83.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $76.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 7.9% | 21.0% |
| 资本支出强度资本支出/营收 | 0.7% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $134.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流DNOWRVTY
| Q4 25 | $83.0M | $182.0M | ||
| Q3 25 | $43.0M | $138.5M | ||
| Q2 25 | $45.0M | $134.3M | ||
| Q1 25 | $-16.0M | $128.2M | ||
| Q4 24 | $122.0M | $174.2M | ||
| Q3 24 | $74.0M | $147.9M | ||
| Q2 24 | $21.0M | $158.6M | ||
| Q1 24 | $81.0M | $147.6M |
自由现金流DNOWRVTY
| Q4 25 | $76.0M | $161.8M | ||
| Q3 25 | $39.0M | $120.0M | ||
| Q2 25 | $41.0M | $115.5M | ||
| Q1 25 | $-22.0M | $112.2M | ||
| Q4 24 | $119.0M | $149.8M | ||
| Q3 24 | $72.0M | $125.6M | ||
| Q2 24 | $18.0M | $136.6M | ||
| Q1 24 | $80.0M | $129.7M |
自由现金流率DNOWRVTY
| Q4 25 | 7.9% | 21.0% | ||
| Q3 25 | 6.2% | 17.2% | ||
| Q2 25 | 6.5% | 16.0% | ||
| Q1 25 | -3.7% | 16.9% | ||
| Q4 24 | 20.8% | 20.5% | ||
| Q3 24 | 11.9% | 18.4% | ||
| Q2 24 | 2.8% | 19.7% | ||
| Q1 24 | 14.2% | 20.0% |
资本支出强度DNOWRVTY
| Q4 25 | 0.7% | 2.6% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 0.6% | 2.6% | ||
| Q1 25 | 1.0% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 0.3% | 3.3% | ||
| Q2 24 | 0.5% | 3.2% | ||
| Q1 24 | 0.2% | 2.7% |
现金转化率DNOWRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.72× | 2.97× | ||
| Q2 25 | 1.80× | 2.49× | ||
| Q1 25 | -0.73× | 3.03× | ||
| Q4 24 | 6.10× | 1.84× | ||
| Q3 24 | 5.69× | 1.57× | ||
| Q2 24 | 0.88× | 2.87× | ||
| Q1 24 | 3.86× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNOW
| Pipelines | $455.0M | 47% |
| Downstream And Industrial | $196.0M | 20% |
| Gas Utilities | $183.0M | 19% |
| Oil And Gas Properties | $105.0M | 11% |
| Other | $20.0M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
